Therapeutic Substances Regulations (Amendment)

Overview

The Therapeutic Substances Act 1953-1959, enacted by the Commonwealth Parliament, was established to regulate the approval, manufacture, and sale of therapeutic substances in Australia. The Act aimed to fill a critical gap in ensuring that therapeutic substances available in the market met safety, quality, and efficacy standards. In 1965, the Therapeutic Substances Regulations were amended to enhance the administration and oversight of therapeutic substances. The amendments were made by the Governor-General in accordance with the Federal Executive Council, seeking to refine the operational aspects of the Act. The policy objective of these amendments was to streamline the regulatory processes and ensure that the committees overseeing these regulations were effectively managed and compensated for their duties.

Scope and Application

The Therapeutic Substances Regulations 1965, made under the Therapeutic Substances Act 1953-1959, apply to the regulation and administration of therapeutic substances within the Commonwealth of Australia. These regulations specifically pertain to the administration and composition of committees formed under the Act, their remuneration and allowances, and the role of the Director-General in these committees. The Director-General is designated as the Chairman of any committee of which he is a member, excluding the Australian Drug Evaluation Committee, and is responsible for overseeing committee operations. Additionally, the Regulations address the financial compensation for committee members, including allowances for travel expenses incurred during committee meetings. These allowances are set by the Minister and are applicable only to absences occurring after the commencement of these Regulations. The amendments to the Regulations are designed to enhance the efficiency and effectiveness of the therapeutic substances regulatory framework, ensuring that committee members are properly compensated for their duties and that the Director-General's role is clearly defined and acknowledged.

Key Provisions

The main operative sections of these Regulations provide amendments to the Therapeutic Substances Regulations under the Therapeutic Substances Act 1953-1959. Specifically, Regulation 22 is amended to designate the Director-General as the Chairman of any Committee of which he is a member, excluding the Australian Drug Evaluation Committee (sub-regulation (1.)). Additionally, sub-regulation (3.) is inserted to clarify that the term 'Committee' does not encompass the Australian Drug Evaluation Committee established under the previous regulation. Furthermore, Regulation 26 is amended to specify that members of a Committee who are required to be away from home overnight for Committee meetings are eligible for a travelling allowance at rates set by the Minister, applicable to their absence (sub-regulation (3.)). This amendment, however, does not apply to absences that began before the commencement of these Regulations. These Regulations impose several obligations and requirements on the parties and entities governed by them. Firstly, the Director-General is mandated to serve as the Chairman for any Committee of which he is a member, except for the Australian Drug Evaluation Committee. This structural change likely aims to streamline leadership and decision-making within relevant committees. Secondly, members of these Committees are entitled to a travelling allowance if they must be away from home overnight for Committee business. This allowance is to be paid at rates determined by the Minister, reflecting the necessity for fair compensation for travel-related expenses incurred during official duties. These provisions ensure that the administrative framework is both efficient and equitable. Breaching the provisions of these Regulations could result in various consequences, though the specific offences and penalties are not detailed within the text. Generally, under the Therapeutic Substances Act 1953-1959, breaches of regulations can lead to administrative penalties, including fines and other sanctions. The maximum penalties for such breaches would typically be determined in accordance with the broader legislative framework governing therapeutic substances in Australia. It is important for the parties involved to adhere to these regulations to avoid any legal repercussions.